AB Corporate Bond ETF (NASDAQ:EYEG) Stock Price Crosses Below 200 Day Moving Average – What’s Next?

Posted by Chris Copeland on Jul 31st, 2026

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $35.38 and traded as low as $34.58. AB Corporate Bond ETF shares last traded at $34.58, with a volume of 415 shares.

AB Corporate Bond ETF Trading Down 0.3%

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07. The company’s fifty day moving average is $35.09 and its 200-day moving average is $35.37. The stock has a market cap of $27.62 million, a PE ratio of -20.55 and a beta of 0.17.

AB Corporate Bond ETF Cuts Dividend

The business also recently declared a monthly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Wednesday, July 1st were given a dividend of $0.1358 per share. This represents a c) annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend was Wednesday, July 1st. AB Corporate Bond ETF’s dividend payout ratio (DPR) is currently -102.98%.

Hedge Funds Weigh In On AB Corporate Bond ETF

A hedge fund recently bought a new position in AB Corporate Bond ETF stock. Jane Street Group LLC bought a new position in AB Corporate Bond ETF (NASDAQ:EYEG – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,496 shares of the specialty pharmaceutical company’s stock, valued at approximately $232,000. Jane Street Group LLC owned about 0.87% of AB Corporate Bond ETF as of its most recent SEC filing. Institutional investors and hedge funds own 64.16% of the company’s stock.

AB Corporate Bond ETF Company Profile

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.